Advertisement

Topics

GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen

19:00 EST 28 Feb 2017 | GlaxoSmithKline

GSK today announced the closure of an agreement with Aspen aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.

Original Article: GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen

NEXT ARTICLE

More From BioPortfolio on "GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...